《大行報告》麥格理料內地醫保藥價談判降幅60%至80% 建議談判結束後撈底藥股
麥格理發表研報指,第五輪醫保談判(NRDL)正式於北京舉行,到目前為止公開資訊有限,估計恆瑞醫藥、百濟神州(06160.HK)及君實生物(01877.HK)可能會將PD-1藥物的價格大幅下調60%至80%,但進口PD-1可能不包括其中,建議投資者在醫保談判結束後撈底。
該行表示,首天的NRDL並未公布正式的降價通知,但最重要PD1藥物的價格討論可能會在12月16日上午進行,預計降價幅度達60%至80%,對藥企及生物技術公司料產生負面影響,板塊股價已經從高位回落約11%至13%,對比同期MSCI中國指數下跌約3%。
麥格理預期,藥企及生物技術公司仍可能會在研發方面投入更多的資金來開發新產品,以減輕政策影響,預期藥明生物(02269.HK)應繼續受惠,予「跑贏大市」評級及目標價87.34元,首選信達生物(01801.HK),予「跑贏大市」評級及目標價76.01元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.